-
Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA’s Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
-
FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-negative Bacteria
-
Economic Reform Can Save Antibiotic Innovation
-
Shionogi Joins the World Economic Forum and Signs the Davos Compact on Antimicrobial Resistance — Contributing to the Resolution of Global Healthcare Challenges, Including AMR, Through International Collaboration
-
Shionogi Receives Contract with U.S. Government Through BARDA’s Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
-
ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (Cefiderocol) in MBL-Producing Enterobacterales Infections
-
SHIONOGI Group’s Efforts to Address AMR Highly Rated — Ranked No. 2 Among Global R&D-Based Pharmaceutical Companies in the Antimicrobial Resistance Benchmark 2026
-
Shionogi Awarded the Minister of Health, Labour and Welfare Award for Cefiderocol at the 8th Japan Medical Research and Development Grand Prize
-
Approval for Cefiderocol in China
-
Shionogi Pharma’s Kanegasaki Plant Receives “BSI Kitemark™ for Minimized Risk of AMR” Certification for Antimicrobial Manufacturing